SCHEDULE: Frazier Life Sciences Amends Arcutis Stake
Beneficial Ownership Update
Frazier Life Sciences and affiliated entities updated their beneficial ownership in Arcutis Biotherapeutics, Inc. via an Amendment No. 7 to their Schedule 13D.
Summary
- Frazier Life Sciences VIII, L.P. and its related entities, along with individuals James N. Topper and Patrick J. Heron, filed an Amendment No. 7 to their Schedule 13D regarding their investment in Arcutis Biotherapeutics, Inc.
- The reporting persons collectively hold a significant stake in Arcutis Biotherapeutics, Inc., with Patrick J. Heron beneficially owning 8,943,712 shares, representing 7.5% of the outstanding Common Stock.
- James N. Topper beneficially owns 8,843,386 shares, representing 7.4% of the outstanding Common Stock.
- The beneficial ownership percentages are calculated based on 119,905,078 shares of Arcutis Biotherapeutics, Inc. Common Stock outstanding as of July 31, 2025.
- The shares were acquired for investment purposes using the working capital of the respective Frazier entities, with no funds borrowed for these acquisitions.
- The reporting persons may acquire or dispose of additional shares based on market conditions and their ongoing evaluation of Arcutis Biotherapeutics, Inc.'s business and prospects.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual update on beneficial ownership and does not contain information that would significantly alter the investment thesis for Arcutis Biotherapeutics, Inc.
Positives
- NA
Negatives
- NA
Risks
- Reporting persons may dispose of or acquire additional shares of the Issuer depending on market conditions, their continuing evaluation of the business and prospects of the Issuer, and other factors.
Future Outlook
Reporting persons may dispose of or acquire additional shares of Arcutis Biotherapeutics, Inc. based on market conditions, their ongoing evaluation of the company's business and prospects, and other factors. No present plans exist for extraordinary corporate transactions, changes in management or board, or alterations to the company's capitalization or dividend policy.
Industry Context
This filing represents a routine disclosure by a significant institutional investor group specializing in life sciences, indicating their continued substantial stake in a publicly traded biotechnology company. Such disclosures are standard practice for large shareholders and provide transparency regarding major investment positions within the biotech sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding the continued significant ownership stake held by Frazier Life Sciences and its affiliates, which may offer some stability signal from a major institutional investor.
Next Steps
- Reporting persons may acquire or dispose of additional shares of Arcutis Biotherapeutics, Inc. in the future.
Key Dates
| Date | Description |
|---|---|
| July 31, 2017 | Power of Attorney filed with the SEC on behalf of James N. Topper and Patrick J. Heron. |
| February 7, 2020 | Original Schedule 13D filed. |
| October 6, 2020 | First amendment to Schedule 13D filed. |
| February 9, 2021 | Second amendment to Schedule 13D filed. |
| May 12, 2021 | Third amendment to Schedule 13D filed. |
| August 9, 2022 | Fourth amendment to Schedule 13D filed. |
| October 26, 2023 | Fifth amendment to Schedule 13D filed. |
| March 6, 2024 | Sixth amendment to Schedule 13D filed. |
| July 31, 2025 | Date of Issuer's Common Stock outstanding count (119,905,078 shares) as reported in the Issuer's Quarterly Report on Form 10-Q. |
| August 6, 2025 | Issuer's Quarterly Report on Form 10-Q filed with the SEC. |
| August 18, 2025 | Date of event which required the filing of this statement. |
| August 20, 2025 | Date of signing of the Joint Filing Agreement and the Schedule 13D Amendment No. 7. |
Recommendation
holdThe filing is a routine amendment to a Schedule 13D, updating beneficial ownership information. It does not provide new operational, financial, or strategic insights into Arcutis Biotherapeutics, Inc. that would warrant a change in investment recommendation. The continued significant stake by a life sciences-focused investment group is noted, but without further company-specific news, a 'hold' recommendation remains appropriate.
Keywords
Arcutis Biotherapeutics, Frazier Life Sciences, Schedule 13D, beneficial ownership, biotech, investment fund, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.